Liberation Labs rebrands as Liberation Bioindustries ahead of commercial launch

Liberation Labs has officially rebranded as Liberation Bioindustries, marking a shift in identity that aligns with the company’s emergence as a global-scale, commercial biomanufacturing partner. The name change, announced this week, reflects the company’s transition from startup phase to active industrial operator as it prepares to bring its first facility online in early 2026.

“With our Richmond plant nearing completion, the ‘Labs’ part of our name felt unnecessarily limiting, if not outright confusing,” commented Mark Warner, Founder & CEO of Liberation Bioindustries. “After all, the world is full of amazing biotechnologies that are at lab scale – we’re building the next generation of industrial biomanufacturing facilities to bring those products to market.”

The company’s rebrand includes a new visual identity, website and communications strategy designed to reflect its positioning as a large-scale contract manufacturer serving a variety of sectors, including food, pharma, specialty ingredients and industrial applications. According to the company, the new brand language emphasizes practical engineering, operational accountability and technical experience, paired with a forward-looking mindset and collaborative ethos.

Liberation Bioindustries is currently completing its first precision fermentation facility in Richmond, Indiana. Once operational, it will offer 600,000 liters of fermentation capacity and feature a dedicated downstream processing line. The plant is intended to meet growing demand from companies seeking to scale up bio-based production but lacking access to purpose-built manufacturing infrastructure.

The site will serve both emerging startups and established consumer goods brands, helping to bridge the persistent 'capacity gap' that has slowed the commercial rollout of many biotechnology innovations.

In May, Liberation Bioindustries announced it will manufacture Vivitein BLG – a beta-lactoglobulin dairy protein – for Dutch ingredients company Vivici at commercial scale. The Richmond facility will be used to produce the ingredient, which is aimed at food and nutrition applications and developed through precision fermentation.

In parallel, the company is expanding internationally. In April, it announced a strategic partnership with Topian, NEOM’s food division, to explore development of a precision fermentation facility in Saudi Arabia. A feasibility study for that project is expected to begin in the second half of 2025.

“The new name, Liberation Bioindustries, reflects both the scale of what we’re building and the diversity of industries we support,” Warner said. “We’re not just making food ingredients. We’re enabling a broader shift toward more sustainable, efficient and scalable bio-based manufacturing.”

Liberation Bioindustries’ emergence comes at a critical time for the precision fermentation sector, which has matured rapidly over the past five years but continues to face challenges in bridging the gap between lab-scale breakthroughs and full industrial production. The company aims to become a foundational manufacturing partner in this space, offering reliable capacity and transparent operations tailored to the specific needs of fermentation-based processes.

The Richmond plant has been designed from the ground up to meet the technical demands of modern bio-based manufacturing, including integrated digital controls and dedicated DSP systems that enable efficient production and purification of complex proteins and other high-value compounds.

Warner, who brings decades of engineering and scale-up experience to the role, has previously emphasized the importance of pragmatic facility design and execution in the success of industrial biotech ventures.